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INTRODUCTION
Around 26 million adults worldwide are living 
with heart failure (HF) that is thus described as a 
“global pandemic”.1 In Indonesia, the prevalence of 
HF is 0.13%.2 Psoriasis is a disease characterized 
by chronic inflammation with a global prevalence 
of 1-2%. It has strong genetic component with a 
systemic immunological response mainly driven 
by T helper (Th) 1 and 17 lymphocytes.2,3 The 
relationship between HF and psoriasis is not well-
described.
By presenting two cases of psoriatic HF patients 
with re-hospitalizations, this manuscript aims 
at highlighting the potential role of psoriatic 
inflammation in worsening HF.
CASE PRESENTATION
First Case
This is a case of a 61-year-old man, who 
regularly visits the outpatient clinic in the National 
Cardiac Center Harapan Kita (NCCHK) every two 
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months. During his last visit, he only admitted 
having slight limitation of physical activity without 
any paroxysmal nocturnal dyspnea (PND) or 
orthophnea. He had a history of valvular disease 
but did not complain of any HF symptoms until the 
age of 51. He then had mitral valve replacement due 
to mitral regurgitation in Penang. The patient also 
had a history of psoriasis diagnosed at the age of 49 
but was not on any psoriasis treatment. There was 
no history of psoriasis exacerbation. The patient 
also denies any history of hypertension, diabetes 
mellitus, smoking, obesity, alcohol abuse, and drug 
use. Family history was negative for cardiovascular 
disease or cardiomyopathy. He reported four prior 
hospitalization in NCCHK due to decompensated 
HF. The first one was two months after surgery. The 
second one was in 2012, the third in 2014, and the 
last in 2016. On physical examination, the patient 
had normal vitals. There was no signs of left or right 
HF. Skin lesions consisting of scales and plaques 
over the extremities were noted. His joints were 
normal. Routine laboratory tests revealed normal 
renal function and normal electrolytes. Chest 
radiography (2016) showed an enlarged heart and 
bilateral pulmonary congestion. Electrocardiogram 
showed sinus rhythm, right bundle branch block 
(RBBB), and multiple PVCs. Echocardiography 
showed general severe hypokinesis, dilatation of 
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left atrium (LA) and left ventricle (LV), severely 
reduced global systolic function and regional wall 
abnormality, mild pulmonal regurgitation (PR), 
mild tricuspid regurgitation (TR), and a well 
functioning mechanic valve with trivial central 
leakage. Coroangiography in 2011 demonstrated 
normal coronary arteries.
Second Case
This is a case of a 58-year-old man who was 
admitted with a 1-month history of dyspnea. One 
month prior to admission, he began suffering 
from shortness of breath on effort, orthopnea, 
and paroxysmal nocturnal dyspnea. His legs and 
abdomen started to swell 3 days before admission. 
The patient had a history of HF diagnosed in 2012. 
He was hospitalized in NCCHK back then. After 
discharge, he did not seek any medical therapy. 
His risk factors included hypertension, smoking, 
and obesity. He denied any family history of 
cardiovascular disease or cardiomyopathy, drug 
use or alcohol consumption. He has had psoriatic 
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Figure 1 (A) skin lesions in the first patient: scales and plaques over the extremities; (B) skin lesions 
in the second patient: plaques over the feet; (C) chest radiograph of the first patient: enlarged heart 
and bilateral pulmonary congestion; (D) chest radiograph of the second patient: enlarged heart and 
mild congestion.
(A) (B)
(C) (D)
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skin lesions for 3 months prior to admission, 
for which no medical treatment was sought. On 
physical examination, the patient had normal vitals. 
However, he did have signs of congestive HF. He 
also has scaly skin lesions and plaques on both of 
his feet. Routine laboratory tests revealed normal 
white blood count and normal renal function. 
Chest radiography showed an enlarged heart and 
bilateral congestion. Electrocardiogram showed 
atrial fibrillation. Echocardiography showed 
generalized severe hypokinesis, dilatation of LA 
and LV, severely reduced global systolic function, 
severe mitral regurgitation, and severe TR. 
Coroangiography in 2012 demonstrated a normal 
left main artery, an irregular left axis deviation, an 
irregular left circumflex artery, and a normal right 
coronary artery (i.e., an insignificant stenosis).
DISCUSSION
Across the globe, 17-45% of patients admitted to 
hospital with heart failure (HF) die within 1 year 
of admission and the majority die within 5 years. 
This “global pandemic” affects 26 million adults. 
In many countries, population-based studies have 
found that 1-2% of people have HF, and similar or 
higher proportions have been reported in single-
center studies.1 Prevalence is variable across nations, 
ranging between 1.5-1.9% in North America, 1-2% 
in Europe, 1-3% in Australia, and as low as 0.13% 
in Indonesia. Interestingly, reported prevalence 
of HF in Malaysia and Singapore exceeds global 
prevalence.1,4 
Psoriasis is a disease of chronic inflammation, 
with a global prevalence of 1-2%, affecting not 
only the skin but also many other systems.3 The 
prevalence of psoriasis in Indonesia has not been 
calculated yet.5 The levels of interleukin 17A (IL-
17A) and TNF-α, both responsible for inflammation 
in psoriasis, are also increased in HF. This 
mechanism is assumed to link both diseases.
Psoriasis
Psoriasis is a common chronic inflammatory 
disease with a strong genetic component 
characterized by a systemic immunological 
response, which is mainly driven by T helper 
(Th) 1 and 17 lymphocytes.6,7 Like other chronic 
inflammatory disorders, including rheumatoid 
arthritis, inflammatory bowel disease, and systemic 
lupus erythematous, psoriasis shares inflammatory 
mechanisms with atherosclerosis and confers an 
independent risk for various cardiovascular diseases 
as myocardial infarction.8 According to current 
guidelines, patients with rheumatoid arthritis and 
other forms of inflammatory arthritis, including 
psoriatic arthritis, should undergo annual evaluation 
of cardiovascular risk factors. There is also evidence 
suggesting that such a recommendation should be 
extended to patients with psoriasis.9
Pathogenesis of Psoriasis and Systemic 
Inflammation10
Chronic inflammation of the skin and joints 
have many common immunopathological features, 
including genetic predisposition, composition of 
inflammatory infiltrates, vascular changes, early 
immune events and proangiogenic similarities. The 
cellular infiltrate is predominantly perivascular. 
B lymphocytes are abundant but the contribution 
of B cells to the pathogenesis is unlikely. T 
lymphocytes are the most abundant in both skin 
and joints, with the dominant types being cytotoxic 
T lymphocyte CTL, T helper 1 (Th1) and T helper 
17 (Th17). Neuropeptides (NP) are also involved in 
proinflammatory pathways. Antigen is presented to 
naive CD4 in lymph nodes. Emerging lymphocytes 
migrate preferentially to skin and joints, where 
the above-mentioned infiltrating T lymphocytes 
(CD4, CD8) interact with local Antigen Presenting 
Cell (APC), such as Langerhans cells, myeloid-
DC and plasmacytoid-DC, to produce chronic 
inflammatory conditions. Local re-activated 
T cells secrete chemokines and cytokines that 
amplify the inflammatory environment, resulting 
in the formation of psoriatic plaque, induction of 
degradation of cartilage and perhaps atherosclerotic 
plaque. Since the suppressive activity of regulatory 
cells is decreased in both tissue and blood, 
lymphocytes show high replicative power. The 
chronic production of proinflammatory cytokines 
[interferron gamma (IFN-γ) and tumor necrosis 
factor (TNF-α)] crucially contributes to the 
perpetuation of the disease. TNF-α is critically 
involved in induction of inflammatory degradation 
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of cartilage and bone. The osteolytic activity is the 
result of the activation of osteoclasts by the action 
of IFN-γ. 
Diagnosis of Psoriasis11
The diagnosis of psoriasis is primarily clinical. 
There are different clinical types of psoriasis, the 
most common being chronic plaque psoriasis, 
affecting 80% to 90% of patients with psoriasis. 
The hallmark of classic plaque psoriasis is well-
demarcated, symmetric, and erythematous plaques 
with overlying silvery scales. Plaques are typically 
located on the scalp, trunk, buttocks, and extremities 
but can occur anywhere on the body. Patients might 
demonstrate nail involvement, which can present 
without concomitant plaques. Active lesions might 
be itchy or painful. Psoriasis can also present as an 
isomorphic response, where new lesions develop 
on previously normal skin that has sustained 
trauma or injury. The severity of disease can be 
helpful in guiding management and is classified 
as mild, moderate, and severe. Less common 
variants of psoriasis include inverse psoriasis, 
pustular psoriasis, guttate psoriasis, erythrodermic 
psoriasis, and annular psoriasis. These variants can 
be differentiated from the common plaque type 
by morphology. Differential diagnoses include 
atopic dermatitis, contact dermatitis, lichen planus, 
secondary syphilis, mycosis fungoides, tinea 
corporis, and pityriasis rosea. Careful observation 
often yields the diagnosis. For more atypical 
presentations, a skin biopsy might be helpful.
Heart Failure12 
Activation of the adrenergic nervous system is an 
important regulator of cardiac performance during 
Figure 2 Immunopathogenesis of psoriasis and psoriatic arthritis associated events 
that worsen the cardiovascular risk profile.
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exertion; it increases myocardial contractility 
and redistributes cardiac output. In acute HF, 
enhanced contractility resulting from adrenergic 
activation stimulates the depressed contractility of 
the failing heart and, by causing vasoconstriction, 
raises the blood pressure and aids in the perfusion 
of vital organs. However, prolonged activation 
of the adrenergic nervous system and of the 
reninangiotensin-aldosterone system causes 
maladaptive remodeling of the ventricles and further 
myocardial injury, thereby initiating a vicious cycle 
in what has become known as the neurohumoral 
model of HF. In HF, there is elevation of C-reactive 
protein (CRP). The concentration of a number of 
pro-inflammatory cytokines, such as TNF-α and 
IL-6, have also been shown to increase in HF. In 
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elderly subjects without HF, abnormal elevation in 
three inflammatory markers (CRP, tumor necrosis 
factor alpha, and IL-6) was reported to be associated 
with a 4-fold increase in the risk of HF. The level of 
these biomarkers was correlated with the severity 
of HF; they appeared to be important predictors of 
the outcome.
Inflammation in HF and Psoriasis
The association of cardiomyopathy and psoriasis 
requires an insight into the possible pathogenetic 
links of these two diseases. The pathogenesis of 
psoriasis is characterized by an increased antigen 
presentation process, increased T lymphocyte 
activity, and upregulation of type 1 helper T 
cytokines.12,13 The etiology of psoriasis is unknown 
and is thought to be a combination of genetic, 
immune and environmental factors. One third of 
psoriatic patients has a first-degree relative with 
psoriasis, and the incidence in monozygotic twins 
is estimated to be 70% compared to dizygotic 
twins, where it is 25%. A number of genes related 
to psoriasis have been identified, but their role and 
function is not clear.13,14 
HF is a systemic disease that has many etiologies 
including genetic factors and immune factors. 
Immune activation leads to production and 
release of pro-inflammatory cytokines, activation 
of the complement system, and production of 
autoantibodies. Gene expression of chemokines 
is upregulated in T cells of patients with HF. This 
activates the immune system through binding to 
the tumor necrosis factor superfamily and their 
receptors. The inflammatory cytokines IFN-γ 
and IL-18 have a similar pattern in ischemic and 
idiopathic cardiomyopathy.13 T helper 1 and T 
helper 2 cytokine imbalance has also been identified 
to play a role in HF pathogenesis.12
IL-17A is a pro-inflammatory cytokine produced 
mainly by Th17 lymphocytes, but also by natural 
killer T cells, gd T cells, cytotoxic CD8+ T cells, 
and neutrophils.13 Multiple lines of evidence from 
animal and human studies suggest crucial roles of 
IL-17A and its receptor interleukin-17 receptor A 
(IL-17RA) in ischemic heart disease.13 Similarly, 
animal studies have provided evidence that IL-17A 
plays an important role in dilated cardiomyopathy 
(DCM). Previous studies have identified Th17/
Treg imbalance with upregulation of IL-17A that 
plays an important role in HF pathogenesis.15 
Recent studies have identified single nucleotide 
polymorphisms (SNPs) in IL-17A/IL-17RA axis 
that contribute to both psoriasis and HF. A recent 
study demonstrated associations of rs8193037 in 
the promoter of IL17A with the risk of congestive 
HF, and of rs4819554 in the promoter of IL17RA 
with the risk of cardiovascular mortality in patients 
with congestive HF.15 
Circulating levels of proinflammatory cytokines 
such as TNF-α, soluble TNF receptors (sTNF-R1 
and sTNF-R2), IL-6 and sCD14 have been shown 
to be independent predictors of mortality in patients 
with advanced HF.13 Several published studies have 
investigated the association between the -308G/A 
(rs1800629) polymorphism in the tumor necrosis 
factor-a (TNF-α) gene and the risk of dilated 
cardiomyopathy (DCM). However, the TNF-α 
gene polymorphism has a controversial role in the 
pathogenesis of DCM among different populations. 
There may be a moderate association between TNF-α 
rs1800629 polymorphism and DCM susceptibility 
in populations studied; however, TNF-α rs1800629 
polymorphism was significantly associated with the 
susceptibility of DCM for Asians, which indicates 
that such associations may be different between 
ethnicities.15
Association Between Clinical Manifestation of 
HF and Severity of Psoriasis9
A few observational studies have previously 
demonstrated an increased risk of HF in patients 
with psoriasis while others have found no such 
association.10 These conflicting results may be 
explained, in part, by methodological issues (e.g. 
differences in population size and adjustments 
for important covariates). Moreover, previous 
studies are mainly based on selected populations 
and so the impact of the severity of psoriasis on 
the risk of HF has not been fully investigated. 
However, one study, which is by far the largest to 
date, add to the evidence provided in the earlier 
studies demonstrating an association between 
psoriasis and HF with an increased risk of new-
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onset HF with increased severity of psoriasis. The 
association remains strong even after adjustments 
for comorbidities, cardiovascular medications and 
socioeconomic status. These results support the 
proposition of independent effects of psoriasis on 
the risk of HF mediated through inflammatory 
mechanisms. It is thus possible that even 
asymptomatic patients with psoriasis are at high risk 
of HF with/without structural heart disease. In the 
study, the overall incidence rates of new-onset HF 
were 2.82, 4.22 and 4.70 per 1000 person-years for 
the reference population, mild psoriasis, and severe 
psoriasis, respectively. This concludes that severity 
of psoriasis led to increased risk of new-onset HF. 
Several case reports about HF in psoriasis patients 
have been published. They are listed in Table 1.
Despite being diagnosed with heart disease 
earlier, the first patient only complained of dyspnea 
at the age of 51 and had mitral valve replacement 
shortly. Two years before symptom exacerbation, 
he had psoriasis on his legs, arms, and elbow. He 
was also hospitalized in 2012, 2014 and 2016 due 
to HF exacerbation. By that time, the psoriasis was 
still uncontrolled. 
The second patient was hospitalized due to HF 
6 years ago in NCCHK. He did not seek medical 
treatment afterwards. He was also obese and had 
hypertension and dyslipidemia. One month prior 
to admission, he experienced dyspnea and is now 
treated for full-blown HF. Also, three months 
before admission, he experienced psoriasis for the 
first time and was not treated. 
In both patients, untreated psoriasis led to HF 
exacerbation. Chronic systemic inflammation 
in psoriasis, if left untreated, will amplify the 
inflammatory state in HF patients thus leading to 
the exacerbation of the HF symptoms. 
Patients with psoriasis carry an excessive risk 
of atrial fibrillation (AF). The differences between 
the maximum (Pmax) and the minimum (Pmin) 
P-wave duration on ECG are defined as P-wave 
dispersion (PWD). Prolongation of PWD is an 
independent risk factor for the development of AF. 
Atrial conduction of sinus impulses was shown to 
be impaired in patients with psoriasis vulgaris. It 
was more prominent in patients with severe disease, 
high disease activity score and hsCRP. Physicians 
caring for patients with psoriasis vulgaris should 
screen them for AF development.11,18 In the first 
patient, there is not any abnormality of PWD 
on ECG. However, the second patient had atrial 
fibrillation but due to unavailability of precious 
electrocardiography, his PWD during sinus rhythm 
could not be evaluated.
CONCLUSION
Psoriasis is a risk factor for the deterioration 
of HF due to uncontrolled inflammation factors. 
It is important to evaluate the disease activity of 
psoriasis to control the HF.
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